SAGE — Sage Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $801.22m
- $48.04m
- $86.46m
- 42
- 21
- 12
- 14
Annual income statement for Sage Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.87 | 1,114 | 6.31 | 7.69 | 86.5 |
| Cost of Revenue | |||||
| Gross Profit | 6.47 | 1,114 | 5.75 | 6.87 | 84.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 715 | 518 | 467 | 555 | 666 |
| Operating Profit | -708 | 596 | -461 | -547 | -580 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -680 | 606 | -458 | -533 | -541 |
| Net Income After Taxes | -680 | 606 | -458 | -533 | -541 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -680 | 606 | -458 | -533 | -541 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -680 | 606 | -458 | -533 | -541 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13.4 | 12 | -7.8 | -8.98 | -8.49 |